^
Association details:
| Biomarker: | PD-L1 overexpression + PD-L2 underexpression |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | Imfinzi (durvalumab) (PD-L1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
The expression of programmed death ligand 2 (PD-L2) in immunosuppressive tumor microenvironment of non-small cell lung cancer (NSCLC) and its potential association with immunotherapy
Published date:
11/08/2019
Excerpt:
...NSCLC patients treated with PD-L1 inhibitor durvalumab...PD-L1 high/PD-L2 low gene expression was associated with low macrophage, fibroblast, and CAF signatures (p<0.05) and numerically improved OS (p=0.15), compared with PD-L1 high/PD-L2 high patients.
Trial ID:
